Drugs / HTL-9936
HTL-9936
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02710188 | Feb → Jul 2016 | Alzheimer disease | Nxera Pharma UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT02546310 | Oct 2015 → Feb 2017 | Alzheimer disease | Nxera Pharma UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT02291783 | Nov 2013 → Jul 2014 | Alzheimer disease | Nxera Pharma UK Limited | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTL-9936 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314959 ↗ |
| Known as | 9936 | “9936, HTL0009936” NCT02291783 ↗ |
| Known as | HTL0009936 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02291783 ↗ |
| Action | Activate | “a selective M1 receptor agonist” NCT02291783 ↗ |
| Modality | Small molecule | — CHEMBL5314959 ↗ |
| Route | Oral | “HTL0009936 single and multiple ascending oral doses.” NCT02291783 ↗ |